Equity
ATHA
Athira Pharma (ATHA)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for ATHA to draw a line in its place.
Have Athira Pharma (ATHA) insiders bought or sold shares recently?
ATHA has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 2 January 2026.
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 02 Jan 2026 | Litton Mark JamesPresident and CEO | Sell | 2,586 | 18K USD |
| 02 Jan 2026 | San Martin JavierCHIEF MEDICAL OFFICER | Sell | 1,644 | 11K USD |
| 02 Jan 2026 | CHURCH KEVINCHIEF SCIENTIFIC OFFICER | Sell | 876 | 6K USD |
| 02 Jan 2026 | Worthington MarkGeneral Counsel and CCO | Sell | 876 | 6K USD |
| 02 Jan 2026 | Renninger RobertChief Financial Officer | Sell | 297 | 2K USD |
| Sold | 5 open-market sales | 6,279 | $43K |
8 other filings: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 31 Dec 2025 | Litton Mark JamesPresident and CEO | Option exercise | 10,834 | |
| 31 Dec 2025 | San Martin JavierCHIEF MEDICAL OFFICER | Option exercise | 4,667 | |
| 31 Dec 2025 | CHURCH KEVINCHIEF SCIENTIFIC OFFICER | Option exercise | 3,667 | |
| 31 Dec 2025 | Worthington MarkGeneral Counsel and CCO | Option exercise | 3,667 | |
| 31 Dec 2025 | Renninger RobertChief Financial Officer | Option exercise | 1,236 | |
| 23 Dec 2025 | PERCEPTIVE ADVISORS LLCDirector | Award | 1,319,026 | 8.4M USD |
| 18 Nov 2025 | CHURCH KEVINCHIEF SCIENTIFIC OFFICER | Award | 1,000 | 2K USD |
| 18 Nov 2025 | Renninger RobertChief Financial Officer | Award | 1,000 | 2K USD |
Which funds hold Athira Pharma (ATHA)?
4 of the 45 institutional funds we track reported a Athira Pharma position for the quarter ended 30 Jun 2026 — a combined 1.2M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Renaissance Technologies | Held (±25%) | 77,424 | 712K USD | +20.6% |
| Millennium Management | Held (±25%) | 32,450 | 298K USD | +2.4% |
| Two Sigma Investments | Held (±25%) | 13,276 | 122K USD | |
| Citadel Advisors | New position | 10,001 | 92K USD |
Have members of Congress traded Athira Pharma (ATHA)?
The most recent congressional trade disclosed in Athira Pharma is a purchase by Sara Jacobs (house, CA), dated 12 Dec 2022.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 12 Dec 2022 | Sara Jacobshouse · Democrat–CA | Purchase | 1K USD–15K USD | 39 days |
| 08 Nov 2022 | Sara Jacobshouse · Democrat–CA | Sale | 1K USD–15K USD | 34 days |
| 18 Jul 2022 | Sara Jacobshouse · Democrat–CA | Purchase | 1K USD–15K USD | 53 days |
Athira Pharma (ATHA): frequently asked questions
Have Athira Pharma insiders bought or sold shares recently?
No Athira Pharma insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 2 Jan 2026 (SEC Form 4). See Insiders
Which funds own Athira Pharma?
4 of the 45 funds we track reported a Athira Pharma position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Renaissance Technologies, Millennium Management and Two Sigma Investments. See Funds
Have members of Congress traded Athira Pharma?
Yes. 3 trades in Athira Pharma appear in the congressional disclosures we hold; the latest is a purchase by Sara Jacobs (House, CA) dated 12 Dec 2022, filed 20 Jan 2023. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- House disclosuresU.S. House of Representatives financial disclosures